Injection Moulding Asia Medical Industry Canadian injection moulding machine supplier Husky Injection Molding Systems has launched the UltraShot Injection System, a next generation melt delivery and control system that eliminates the deficiencies of traditional injection moulding processes and enables manufacturers to mould a quality part at scale. The UltraShot Injection System’s advanced injection control technology enables riskfree scalability with flawless part capability. Additionally, identical system behaviour for each injection circuit provides process Husky’s UltraShot Injection System features an advanced injection control condition consistency technology for risk-free scalability with cavitation scaling. A predictable process from pilot to high cavitation – scalable to 128 cavities, enables producers to maximise cavitation without negative performance on balance or shot-to-shot variation. Brand owners can accelerate from prototype to high cavitation production qualification, thus greatly increasing speed-to-market. As explained by Husky, the Altanium mould controller-powered UltraShot enables brand owners to produce functional and validated parts, economically, where conventional moulding processes cannot. This cavity filling control and process optimisation overcomes traditional constraints of pressure, L/T and difficult-tomould resins. This enables part lightweighting for resin and process time savings and provides resin selection flexibility. Ultimately, this means greater part design freedom, opening up endless possibilities for brand owners looking to take plastic part designs to the next level. The technology is ideal for medical, technical packaging and consumer electronic part producers looking to scale up, implement more efficient process control, address competitive marketplaces, and reduce risk, scrap, waste and cost, Husky said.
infectious materials and meets the IATA (International Air Transport Association) requirements for shipping hazardous liquids on air transport. Each bag is made with a custom film structure that features a strong adhesive closure and continuous seal, which makes it ideal for critical liquid and substance containment. Along the same vein, Toronto-based plastic products manufacturer Viva Healthcare Packaging is also augmenting production of its three-ply medical grade face masks to over 22.5 million/month by early 2021. Viva has received an Ontario Together Fund investment of US$450,000, intended to increase Ontario’s stockpile of locally made PPE. It is using the fund to retool operations and expand production of PPEs. Viva also plans to add two high output face mask-making lines that will run 24/7 with inventory sufficient to support quick deliveries, it said. Viva has three locations worldwide, including Canada (Toronto), its flagship factory Viva is utilising a grant to retool its operations and expand production of equipped with 200 its locally-made PPEs injection moulding machines; Poland and Hong Kong. Confirmed case of swabs market growth The growing cases of Covid-19 are stepping up early detection efforts, auguring demand for testing swabs. Fortune Business Insights forecasts the value of medical swabs market to reach US$4 billion by end of 2027, growing at a rate of 6.9% from 2020. iMFLUX, a subsidiary of Procter &Gamble (P&G), that is focused on mould design and process technology for the injection moulding market, has teamed up with Rhinostics, a company that aims to “revolutionise lab workflows”, for its novel fully injection-moulded PP nasal swab. P&G is licensing its new nasal swab to Rhinostics to launch and bring to the clinical laboratory market. These swabs reduce handling and lab processing cycle time and increase lab capacity as new home collection kits expand rapidly into the virus detection market, according to P&G. Rhinostics, with a plan to registering the P&G PP nasal swab as a Class I Exempt medical device, is said to pursue Emergency Use Authorisation for home collection with rPT-PCR testing.
Materials cater to medical devices The pharmaceutical industry, meanwhile, can benefit from Belgian chemical company’s Solvay’s Udel PSU resins, as can TBL Performance Plastics, which manufactures non-metallic single-use systems and components for the bio-pharmaceutical industry. TBL is utilising Solvay’s resin to achieve the properties like strength, transparency, heat resistance, hydrolytic stability and retention of mechanical properties under steam sterilisation. The FDA 21 CFR 177.1655-compliant PSU resin is a tough, rigid, high-
P&G and Rhinostics collaborated to launch and market an injection-moulded PP nasal swab
Boosting capacities with new technologies Adequate PPE supply relies on efficient machine and materials technology to enable large-scale production. 2 MARCH 2021
www.injectionmouldingasia.com